title: Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
authors.affiliation: a Department of Internal Medicine , The University of Texas Health Sciences Center at Houston , TX , USA.|b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Abhishek
authors.initials: A
authors.lastname: Maiti
authors.affiliation: b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.affiliation: b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferrajoli
authors.affiliation: b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Zeev
authors.initials: Z
authors.lastname: Estrov
authors.affiliation: b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Gautam
authors.initials: G
authors.lastname: Borthakur
authors.affiliation: b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.affiliation: b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Elias
authors.initials: E
authors.lastname: Jabbour
authors.affiliation: b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
authors.affiliation: c Chao Family Comprehensive Cancer Center, University of California , Irvine , CA , USA.
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.affiliation: b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001752:Blast Crisis; D005260:Female; D006248:Harringtonines / Q000008:administration & dosage; D000077863:Homoharringtonine; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D015465:Leukemia, Myeloid, Accelerated Phase; D015466:Leukemia, Myeloid, Chronic-Phase; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D019233:Retreatment; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006248:Harringtonines; D000077863:Homoharringtonine; D000068877:Imatinib Mesylate